Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
Saved in:
| Title: | Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. |
|---|---|
| Authors: | Morris, J. A.1 jon.morris@prosanos.com, Hanson, J. E.1, Steffen, B. J.1, Chu, A. H.1, Chi-Burris, K. S.1, Gotz, V. P.1, Gordon, R. D.1 |
| Source: | Clinical Transplantation. Jun2005, Vol. 19 Issue 3, p340-345. 6p. 4 Charts. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
